Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) Short Interest Up 5.7% in December

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) saw a large growth in short interest in the month of December. As of December 15th, there was short interest totalling 85,300 shares, a growth of 5.7% from the November 30th total of 80,700 shares. Approximately 7.8% of the company’s stock are short sold. Based on an average daily trading volume, of 70,100 shares, the short-interest ratio is currently 1.2 days.

Cadrenal Therapeutics Price Performance

CVKD opened at $14.65 on Thursday. The stock has a market cap of $26.12 million, a P/E ratio of -2.19 and a beta of 1.22. Cadrenal Therapeutics has a fifty-two week low of $5.40 and a fifty-two week high of $32.55. The business’s 50-day moving average price is $14.74.

Analysts Set New Price Targets

Separately, HC Wainwright upped their price target on shares of Cadrenal Therapeutics from $3.00 to $32.00 and gave the stock a “buy” rating in a research note on Monday, November 11th.

About Cadrenal Therapeutics

Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome.